Description: Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
Home Page: www.genorbio.com
Building 3
Shanghai,
201203
China
Phone:
86 21 6169 0700
Officers
| Name | Title |
|---|---|
| Dr. Feng Guo Ph.D. | CEO & Chairman |
| Mr. Chengyi Weng | VP of Fin. |
| Qibin Liang | Chief Technology Officer |
| Dr. Shuhua Han Ph.D. | Chief Scientist |
| Ms. Xiaojing Zhu | VP of Compliance & Admin. |
| Mr. Tong Li | Chief Medical Officer |
| Cheery Chen | Chief Regulatory Officer |
| Mr. Tak Wai Ip | Company Sec. |
| Mr. Jun Lin | VP of Quality Analysis |
| Ms. Yao Chen | VP of Regulatory Affairs |
Exchange: HK
Country: HK : Hong Kong
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6163 |
| Price-to-Sales TTM: | 466.5474 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 452 |